Jefferies Group Brokers Increase Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Jefferies Group upped their FY2019 earnings per share estimates for shares of Vanda Pharmaceuticals in a report released on Tuesday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will post earnings per share of $1.39 for the year, up from their previous estimate of $1.38. Jefferies Group has a “Buy” rating and a $21.00 price target on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ FY2020 earnings at $1.31 EPS and FY2021 earnings at $1.73 EPS.
Other analysts have also recently issued research reports about the stock. Piper Jaffray Companies set a $23.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. HC Wainwright set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Oppenheimer Holdings, Inc. set a $21.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. TheStreet upgraded shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Finally, Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $21.25.
TRADEMARK VIOLATION WARNING: “Jefferies Group Brokers Increase Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/jefferies-group-brokers-increase-earnings-estimates-for-vanda-pharmaceuticals-inc-vnda/1532336.html.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded up 1.042% during mid-day trading on Wednesday, hitting $16.975. The stock had a trading volume of 331,040 shares. The stock’s market cap is $761.46 million. Vanda Pharmaceuticals has a 52 week low of $12.70 and a 52 week high of $18.00. The stock has a 50-day moving average price of $16.10 and a 200 day moving average price of $14.88.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.18. The company had revenue of $42.06 million during the quarter, compared to the consensus estimate of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The company’s revenue was up 16.7% on a year-over-year basis. During the same period last year, the firm earned $0.01 earnings per share.
A number of hedge funds have recently modified their holdings of the company. Strs Ohio boosted its stake in shares of Vanda Pharmaceuticals by 4.6% in the first quarter. Strs Ohio now owns 49,600 shares of the biopharmaceutical company’s stock valued at $694,000 after buying an additional 2,200 shares during the period. Algert Global LLC boosted its stake in shares of Vanda Pharmaceuticals by 11.8% in the first quarter. Algert Global LLC now owns 18,223 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,927 shares during the period. Capital Fund Management S.A. acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $195,000. Birchview Capital LP boosted its stake in shares of Vanda Pharmaceuticals by 145.5% in the first quarter. Birchview Capital LP now owns 54,000 shares of the biopharmaceutical company’s stock valued at $756,000 after buying an additional 32,000 shares during the period. Finally, Virginia Retirement Systems ET AL acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $193,000. Institutional investors and hedge funds own 86.49% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.